Gilead Axes Phase III Magrolimab Trial Based on Disappointing Data

Gilead Axes Phase III Magrolimab Trial Based on Disappointing Data

Submitted by admin on September 27, 2023 - 11:12pm
Source: 
BioSpace
News Tags: 
Gilead Sciences
magrolimab
clinical trials
blood cancers
Headline: 
Gilead Axes Phase III Magrolimab Trial Based on Disappointing Data
snippet: 

Gilead Sciences’ anti-CD47 antibody has again disappointed in a Phase III blood cancer trial. The biopharma announced the decision to discontinue another late-stage study of magrolimab Tuesday. 

Do Not Allow Advertisers to Use My Personal information